216 related articles for article (PubMed ID: 34503080)
1. Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [
Hartrampf PE; Lapa C; Serfling SE; Buck AK; Seitz AK; Meyer PT; Ruf J; Michalski K
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503080
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
Michalski K; Ruf J; Goetz C; Seitz AK; Buck AK; Lapa C; Hartrampf PE
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2024-2030. PubMed ID: 33336265
[TBL] [Abstract][Full Text] [Related]
3. Value of Combined PET Imaging with [
Khreish F; Ribbat K; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Schreckenberger M; Ezziddin S; Rosar F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439287
[TBL] [Abstract][Full Text] [Related]
4. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
[TBL] [Abstract][Full Text] [Related]
6. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract][Full Text] [Related]
7. Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.
Burgard C; Engler J; Blickle A; Bartholomä M; Maus S; Schaefer-Schuler A; Khreish F; Ezziddin S; Rosar F
Front Med (Lausanne); 2023; 10():1339160. PubMed ID: 38298510
[TBL] [Abstract][Full Text] [Related]
8. Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC.
Laarhuis BI; Janssen MJR; Simons M; van Kalmthout LWM; van der Doelen MJ; Peters SMB; Westdorp H; van Oort IM; Litjens G; Gotthardt M; Nagarajah J; Mehra N; Privé BM
Clin Genitourin Cancer; 2023 Oct; 21(5):e352-e361. PubMed ID: 37164814
[TBL] [Abstract][Full Text] [Related]
9. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
10. Neuron-specific enolase has potential value as a biomarker for [
Rosar F; Ribbat K; Ries M; Linxweiler J; Bartholomä M; Maus S; Schreckenberger M; Ezziddin S; Khreish F
EJNMMI Res; 2020 May; 10(1):52. PubMed ID: 32449086
[TBL] [Abstract][Full Text] [Related]
11. Total Tumor Volume on
Unterrainer LM; Beyer L; Zacherl MJ; Gildehaus FJ; Todica A; Kunte SC; Holzgreve A; Sheikh GT; Herlemann A; Casuscelli J; Brendel M; Albert NL; Wenter V; Schmidt-Hegemann NS; Kunz WG; Cyran CC; Ricke J; Stief CG; Bartenstein P; Ilhan H; Unterrainer M
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625683
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
14. PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under
Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208246
[No Abstract] [Full Text] [Related]
15. In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2
Prasad V; Huang K; Prasad S; Makowski MR; Czech N; Brenner W
Front Oncol; 2021; 11():578093. PubMed ID: 33816225
[TBL] [Abstract][Full Text] [Related]
16. Outcome and safety of rechallenge [
Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
[TBL] [Abstract][Full Text] [Related]
17. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [
Ahmadzadehfar H; Matern R; Baum RP; Seifert R; Kessel K; Bögemann M; Kratochwil C; Rathke H; Ilhan H; Svirydenka H; Sathekge M; Kabasakal L; Yordanova A; Garcia-Perez FO; Kairemo K; Maharaj M; Paez D; Virgolini I; Rahbar K
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4067-4076. PubMed ID: 34031719
[TBL] [Abstract][Full Text] [Related]
18. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
20. Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients.
Kesavan M; Meyrick D; Gallyamov M; Turner JH; Yeo S; Cardaci G; Lenzo NP
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33799431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]